Ondasat-MD Tablet contains Ondansetron 4 mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative procedures. Ondansetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting, at the 5-HT3 receptors located centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract. This mechanism effectively reduces the incidence and severity of emesis in patients undergoing emetogenic treatments. Ondasat-MD is indicated for adults and pediatric patients for the management of acute and delayed nausea and vomiting. The tablet formulation ensures convenient oral administration with rapid absorption and onset of action. It is generally well-tolerated, with common adverse effects including headache, constipation, and dizziness. Ondasat-MD should be used with caution in patients with hepatic impairment, and dose adjustments may be necessary. Contraindications include hypersensitivity to ondansetron or any component of the formulation. Careful consideration is advised when co-administered with other serotonergic agents due to the risk of serotonin syndrome. Ondasat-MD Tablet is an effective antiemetic agent that improves patient comfort and compliance during emetogenic therapies.